Israeli Ministry of Health Approves Intravenous Dosing of Remodulin(R) to Treat Pulmonary Arterial Hypertension
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Israeli Ministry of Health Approves Intravenous Dosing of Remodulin(R) to Treat Pulmonary Arterial Hypertension

SILVER SPRING, MD, and RESEARCH TRIANGLE PARK, NC -- January 11, 2006 -- United Therapeutics Corporation announced that the Drug Registration Department of the Israeli Ministry of Health has expanded the label of Remodulin(R) (treprostinil sodium) Injection to include intravenous infusion for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders.

The Israeli approval represents the third national approval of intravenous Remodulin following United States Food and Drug Administration approval on November 24, 2004 and the Canadian Therapeutic Products Directorate approval on October 6, 2005. United Therapeutics has also submitted a marketing application for intravenous Remodulin in France, with filings in additional countries planned during 2006.

"We and our Israeli distribution partner, Pharmateam Marketing, are very pleased with this authorization to offer intravenous Remodulin to patients and physicians in Israel," said Martine Rothblatt, PhD, United Therapeutics Chairman and CEO. "Since 2002 the Israeli market has been an important trailblazer for United Therapeutics."

United Therapeutics is a biotechnology company focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.

SOURCE: United Therapeutics Corporation

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities